Here are 1-3 brief analogies to describe Creative Medical Technology (CELZ):

• Like a **Vertex Pharmaceuticals** focused on stem cell and regenerative medicine.
• Like a **CRISPR Therapeutics** for biologic and stem cell-based therapies.
• Like an **early-stage Amgen** developing innovative stem cell and biologic treatments.

• Allogeneic Stem Cell Therapies: Therapeutic products derived from donor stem cells targeting a range of conditions including neurodegenerative, metabolic, and inflammatory diseases.
• Exosome Therapeutics: Products utilizing exosomes, which are cell-free components derived from stem cells, for regenerative and immunomodulatory applications.
• Point-of-Care Stem Cell Processing Devices: Medical devices designed for the rapid isolation and preparation of a patient's own stem cells for immediate therapeutic administration.

Creative Medical Technology (symbol: CELZ) is a clinical-stage biotechnology company focused on the development of regenerative cell-based therapeutics. As a development-stage company, CELZ is primarily engaged in research and development and managing clinical trials for its various therapeutic candidates.

Currently, CELZ does not have major commercial customers because its product candidates are still in various stages of clinical development and have not yet received regulatory approval for commercial sale. Therefore, the company does not generate significant revenue from product sales to either other companies or individuals.

In the future, should their product candidates receive regulatory approval, their business model would likely involve:

• Selling or licensing their developed therapies to larger pharmaceutical companies (B2B model).
• Potentially selling directly to specialized medical institutions (e.g., hospitals, clinics) that administer advanced cell therapies (B2B model).

However, at this time, there are no identifiable major customers to list.

Timothy Warbington, CEO & Co-Founder

Timothy Warbington is an accomplished entrepreneur and healthcare executive, best known as the founder and CEO of Creative Medical Technology Holdings (NASDAQ: CELZ). He has over 12 years of experience in the healthcare industry and is recognized as an innovator and leader in regenerative medicine. Warbington earned a Bachelor's degree in Accounting from Arizona State University in 1984. For over two decades, he was a principal of a leading agriculture company, owning and operating a multi-million dollar national agricultural (produce) and finance company from 1993 to 2007. In 2006, he began investing in early-stage biotech companies, which led to consulting roles with Boards of Directors and Executives in companies where he held a position, contributing to increased valuations and successful exits. Warbington founded Creative Medical in 2011 to revolutionize regenerative medicine and has served as the company's CEO and President during various periods, including his current tenure since February 2016.

Donald Dickerson, Chief Financial Officer

Donald Dickerson serves as the Chief Financial Officer and Senior Vice-President and Director of Creative Medical Technology Holdings. He was mentioned as the CFO during an investor webinar on October 1, 2024. As of November 3, 2023, he was 58 years old.

Courtney Bartlett, Director of Clinical Development

Courtney Bartlett holds the position of Director of Clinical Development at Creative Medical Technology Holdings.

The emergence of advanced gene editing technologies, such as CRISPR-Cas9, presents a clear emerging threat. While Creative Medical Technology (CELZ) primarily focuses on developing regenerative medicine using stem cell-based therapies for various conditions including neurological, autoimmune, and metabolic disorders, gene editing platforms offer an alternative, and potentially more precise and durable, therapeutic modality. These technologies can directly modify genes or cells (including immune cells and somatic cells) to correct underlying genetic defects or alter cellular function, potentially offering a different and superior approach to treating diseases that CELZ aims to address with cell transplantation or modulation. As gene editing therapies continue to advance rapidly through clinical trials and gain regulatory approvals for a broadening range of indications, they could disrupt the market for certain traditional cell-based therapies by providing a more fundamental or permanent solution to disease, akin to a paradigm shift in how advanced therapies are delivered.

Creative Medical Technology (CELZ) is a biotechnology company focused on regenerative medicine therapies across various fields, including immunology, endocrinology, urogynecology, and orthopedics. The company's main products and services, along with their addressable market sizes and regions, are as follows:

• ImmCelz® (CELZ-100/CELZ-101) for Type 1 Diabetes: The global Type 1 Diabetes market is estimated at USD 16.97 billion in 2025 and is expected to reach USD 26.22 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.4% from 2025 to 2032.
• AlloStem™ (CELZ-201) for Type 1 Diabetes: The global Type 1 Diabetes market is estimated at USD 16.97 billion in 2025 and is expected to reach USD 26.22 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.4% from 2025 to 2032. The U.S. Type 1 Diabetes market size was USD 11.23 billion in 2024 and is anticipated to reach approximately USD 24.27 billion by 2034, with a CAGR of 8%.
• AlloStemSpine (CELZ-201-DDT) for Chronic Lower Back Pain (Degenerative Disc Disease): The global spinal disorders treatment market is projected to exceed USD 20 billion by 2030.
• ImmCelz® for Immuno-Oncology (various indications, including potential solid tumor carcinoma): The global Immuno-Oncology Cell Therapy Market is valued at USD 11.9 billion in 2024 and is predicted to reach USD 95.3 billion by 2034, at a CAGR of 23.2% during the forecast period of 2025-2034. The broader global immuno-oncology (IO) market size was estimated at USD 43.73 billion in 2023 and is projected to reach approximately USD 284.29 billion by 2033.
• ImmCelz® for Stroke Recovery: The global stroke market was valued at USD 33.00 billion in 2024 and is expected to reach USD 58.93 billion by 2032, growing at a CAGR of 7.8% from 2024 to 2032.
• CaverStem™ for Erectile Dysfunction Treatment: The global erectile dysfunction drugs market size was estimated at USD 2.93 billion in 2024 and is predicted to be worth approximately USD 6.74 billion by 2034, expanding at a CAGR of 8.69% from 2025 to 2034. North America dominated this market in 2024.
• FemCelz™ for Female Sexual Function Treatment: null
• iPSCelz (Induced Pluripotent Stem Cell platform): null (currently in pre-clinical stage and early development, broader regenerative medicine market discussed below).
• Alova/OvaStem for Infertility/Premature Ovarian Failure: null
• XoFlo (Exosome enrichment product for musculoskeletal and soft tissue injuries, skin rejuvenation, and scar reduction): null
• Regenerative Medicine Industry (General): The broader regenerative medicine industry is projected to grow to USD 79.23 billion by 2026 globally.

1. Advancement and Commercialization of Clinical Programs: A primary driver will be the successful progression and potential commercialization of its FDA-cleared clinical programs. Specifically, the CELZ-201-DDT (ADAPT Trial) targeting chronic lower back pain due to degenerative disc disease, an estimated $11 billion annual market, is expected to have topline results in the first half of 2026. Additionally, the CELZ-201 (CREATE-1 Trial) for new-onset Type 1 Diabetes, a global treatment market estimated at $35 billion annually, is anticipated to provide early data in 2026. These programs are identified as "major potential near-term catalysts" targeting "multi-billion-dollar markets."
2. Expansion and Application of the ImmCelz Platform: The ImmCelz platform is a core differentiator for the company, possessing "Multi-Billion Dollar Indication Potential." Recent patent acquisitions in Q3 2025 have broadened ImmCelz's coverage to include Type 1 Diabetes and Heart Failure, with patents extending to 2043 and 2042, respectively, thereby securing long-term exclusivity in these high-value markets. This platform, which utilizes a patient's own immune system to initiate regeneration, could unlock revenue streams across various chronic inflammatory and autoimmune conditions.
3. Leveraging AI Integration for Accelerated Development: Creative Medical's integration of Artificial Intelligence (AI) into its iPScelz platform is expected to enhance the efficiency and precision of its therapeutic development. This AI-driven approach aims to accelerate target discovery, optimize donor selection, and model in-vivo behavior, ultimately reducing development time and costs. This "Regenerative Medicine 2.0" strategy could lead to a faster pipeline of new products and services, contributing to future revenue growth.
4. Monetization of Intellectual Property and Existing Products: With a robust intellectual property portfolio of over 60 patents and pending applications, Creative Medical is positioned to generate revenue through licensing agreements. While current revenue is minimal, the company is a "commercial-stage biotechnology company" that offers products like CaverStem for erectile dysfunction and FemCelz for genital sensitivity and dryness. The successful commercialization and increased market penetration of these existing products, alongside new offerings resulting from its extensive patent portfolio and clinical successes, will contribute to revenue.

Share Repurchases

• On June 12, 2023, Creative Medical Technology Holdings, Inc. authorized a share repurchase program for up to $2 million of its common stock.
• As of December 31, 2024, the company had repurchased 101,250 shares of common stock under this plan for an aggregate purchase price of $445,916.

Share Issuance

• In March 2025, the company raised approximately $3.7 million through warrant exercise inducements.
• In October 2025, Creative Medical Technology Holdings generated approximately $4.2 million in gross proceeds from the immediate exercise of existing warrants and subsequently issued new unregistered warrants to purchase up to 2,790,340 shares of common stock.
• The company completed a registered direct offering and a concurrent private placement in October 2024, which collectively raised approximately $1.6 million through the sale of common stock and warrants.
• The company increased its authorized shares of common stock from 5,000,000 to 25,000,000 as of its December 31, 2024 filing.

Inbound Investments

• Creative Medical Technology Holdings received approximately $3.7 million in March 2025 from warrant exercises by certain holders.
• In October 2025, the company secured approximately $4.2 million in gross proceeds from the immediate exercise of outstanding warrants.
• Approximately $1.6 million was raised in October 2024 through a registered direct offering and a concurrent private placement.

Capital Expenditures

• For the nine-month period ended September 30, 2024, research and development expenses increased to $1,928,937 from $1,621,231 in the prior year, primarily due to increased costs associated with clinical trials.
• As of December 31, 2022, the company believed its cash and certificates of deposit were sufficient to meet anticipated operating costs and capital expenditure requirements through at least March 2024.
• Operating expenses in Q3 2025 included ongoing R&D, partly offset by lower R&D as the AlloStemSpine ADAPT trial progressed through recruitment.